Search Results
Search results for "pain neuroscience"
Results found for "pain neuroscience"
- The Imprecision Problem: Why Your GPCR Drug Discovery Program Is Off-Track Before It Even Starts
And when you chain your highest-paid scientists to repetitive admin work, you’re not solving problems That’s a chaos tax — and you’re paying it in cash, time, and morale.
- Inside the New Dr. GPCR Ecosystem: Learning, Insight, and Momentum for 2026
Listeners will gain perspective on: Assay choice as strategy , not convenience.
- Target Residence Time: The Hidden Driver of In Vivo Efficacy
In This Session, You’ll Gain: ✅ Modeling tools to understand how restricted diffusion  in tissues like
- G protein-coupled receptors that influence lifespan of human and animal models
substantial participation in a wide variety of processes of human pathophysiology and are one of the main
- How GPCR Spatial Signaling Sparked a Scientific Journey
Pay attention to that. What began as a quiet obsession soon demanded a bigger stage. control localised signaling, how disease hijacks these systems, and how to target them for therapeutic gain
- A new Kunitz-type snake toxin family associated with an original mode of interaction with the...
We aimed to exploit other mamba venoms to enlarge the V2R-Kunitz peptide family and gain insight into
- TLR4 biased small molecule modulators
Currently, attention was mainly paid to biased signaling modulators targeting G protein-coupled receptors
- Why “Displacement” Misleads You: Allosteric Binding Demystified
In This Session, You’ll Gain: ✅ A clear explanation of why allosteric modulators don’t displace ligands—they
- Differential binding of Δ9-tetrahydrocannabinol derivatives to type 1 cannabinoid receptors (CB1)
Introduction Cannabinoid receptors are GPCRs, and two main types exist, CB1R and CB2R.
- Why Intracellular Drugs May Hold the Key to GPCR Therapeutics
In this session, you’ll gain: ✅ A clear breakdown of how intracellular vs. extracellular receptor access
- Early Safety Assays: Identifying Showstoppers in GPCR Drug Discovery Pipelines Early
In this session, you’ll gain: Clarity on high-impact early safety assays and their compelling rationale
- The Hidden Operating Cadence That’s Actually Driving Your Biotech
Many early-stage biotechs show the same pattern: strong scientific progress paired with an operating discipline, the organization typically shifts from “busy but slightly lost” to “focused, aligned, and gaining
- How System-Level GPCR Thinking Prevents Discovery Failures
What You’ll Gain Spot false confidence early  → Sensitivity differences can turn full agonists into partials
- How GPCR Collaboration Built an Innovation Engine
Monash team built rotational PhD cohorts  — students cycled through multiple groups in their first year, gaining
- GPCR Selectivity Beyond the Receptor — Live April 9th with Bryan Roth
arrestin coupling — and whether the molecular glue framing offers a productive framework for targeting gain
- How to Use Statistical Methods to Strengthen Every GPCR Drug Discovery Decision
Gain career inspiration from Ajay’s bold questions and pivots.
- Purpose-Driven Opioid Research: Catherine Demery’s Academic Path
Like many young scientists, she explored different paths and gained industry experience before realizing
- Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic ...
Gaining control over disease-related events in non-alcoholic steatohepatitis (NASH), an advanced form
- Better GPCR Drug Discovery Decisions Start With Structured Learning
What you gain: Detect scaffold liabilities early—hERG inhibition, mutagenicity, and mechanistic red flags
- Why Mastering Pharmacokinetics Fundamentals Still Defines Discovery Success Today
In This Session, You’ll Gain Clarity on how ADME governs translational success A deeper understanding
- Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of ...
While several gain-of-function mutations that lead to C-terminal truncations, frame shifts and point
- Structural dynamics of Smoothened (SMO) in ciliary membrane and its interaction with membrane lipids
the interactions of SMO with cholesterol and other lipid molecules in the ciliary membrane, and to gain
- Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5...
receptors (SSTs) are class A GPCRs abundantly expressed in pituitary tumors where they represent the main
- Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR
Deep mutational scanning, for instance, is gaining popularity as a strategy due to its ability to comprehensively
- Curve Shifts Don’t Lie, But Your Eyes Might
In This Session, You’ll Gain: ✅ The ability to calculate how many replicates you really  need for 95% By comparing two means (paired or unpaired) you’ll learn whether the divergence is genuine or whether
- Your GPCR Program Decisions Depend on Good Data Interpretation
GPCR Premium Members this week gain curated, early access to: Industry insights : GPCRs and mRNA in drug At Alkermes, Sokhom Pin built an in vitro pharmacology group from scratch—not just a lab, but a culture
- Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism
In this session, you’ll gain: A clear conceptual map of Schild analysis and its origins.
- Accelerating GPCR Drug Discovery: What 40 Years of Pharmacology Reveal
In this session, you’ll gain: ✅ Proven strategies  to balance in vitro vs. in vivo testing early — when
- Orthosteric vs. Allosteric Interactions: The Silent Decider of Safety and Success
In this session, you’ll gain: ✅Clarity on Definitions:  What truly distinguishes orthosteric from allosteric
- Why Opposing Processes Matter for Your Next GPCR Drug
In this session, you’ll gain: ✅ A mental model you can trust  for predicting how GPCR ligands behave























